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Abstract 
MicroRNAs (miRNAs) are post-transcriptional inhibitory regulators of gene expression by 
binding to complementary messenger RNA (mRNA) transcripts. Extracellular miRNAs are 
transported by membrane-derived vesicles (exosomes and microparticles), lipoproteins, and 
other ribonucleoprotein complexes. Extracellular microRNA are emerging as important 
mediators of intercellular communications, being involved in the transmission of biological 
signals between cells. Several miRNAs have been identified as having a primary impact on 
many biological processes that are of direct relevance to cardiovascular complications of 
diabetes. Whether the extracellular miRNAs are directly involved in the regulation of these 
processes is yet to be established. Here, we review recent progresses in extracellular miRNA 
biology and the role of extracellular miRNA in diabetes induced cardiovascular disease, 
describing the regulators affecting miRNA transport and the mechanisms for different miRNA 
transporters. In addition, we discuss the advancement of the research in this field and identify 
the associated challenges. 
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Introduction  
Diabetes mellitus is a chronic metabolic disorder that is characterized by defects in both 
insulin secretion and insulin action. The disease is strongly associated with both microvascular 
(retinopathy, nephropathy, neuropathy, and microangiopathy in different tissues) and 
macrovascular (coronary artery disease –CAD-, peripheral arterial disease –PAD- and 
cerebrovascular disease) complications [1]. Diabetes is an independent risk factor for 
cardiovascular disease (CVD). Several epidemiological and clinical studies have contributed to 
show higher prevalence of heart disease among diabetics as compared to non-diabetic 
subjects. Moreover, due to the presence of concomitant risk factors, diabetics tend to 
develop heart disease at an earlier age [2]. However the asymptomatic nature of the disease 
makes early detection difficult. The prevalence of diastolic dysfunction is as high as 40-60% in 
type 2 diabetics [3]. Moreover, the prevalence of myocardial dysfunction and heart failure 
(HF) was almost twice in diabetics [4]. Interestingly even after reducing other risk factors such 
as hypertension, CAD and obesity, diabetes still remained as an independent risk factor for 
development of CVD [5]. Prevalence of diabetes has been shown to enhance fatty acid 
metabolism, impairing glucose oxidation and intracellular signalling eventually leading to 
adverse cardiac remodelling [6].  
There are sparse evidences, including by us, that intracellular and extracellular microRNAs 
(miRNAs) play important roles in regulating diabetes and diabetes mimicking conditions [7-
10].    
MicroRNAs (miRNAs) are small non-coding RNAs of approximately 22-nucleotides, which have 
increasingly been recognized as potent post-transcriptional regulators of gene expression 
[11]. The specificity of miRNA targeting is generally defined by the complementarities 
between positions 2 to 8 of miRNA 5′-end (also termed the seed sequence) with the 3′ 
untranslated region of target messenger RNAs (mRNAs). The capacity of miRNAs to 
simultaneously inhibit many different mRNAs allows for an amplification of the biological 
responses emanating from miRNA expressional changes [12].  
The surprising observation that some miRNAs are also abundantly present in cell-free blood 
derivatives such as plasma and serum was made by several independent research groups 
(reviewed [13]).  Being embedded in extracellular vesicles (EVs), such as exosomes, 
microvesicles and apoptotic bodies, partially justifies the resistance of miRNAs released 
outside the cell from nucleases [14, 15]. The assumption that extracellular miRNAs are mainly 
present in body fluid encapsulated in exosomes and microvesicles was challenged by several 
studies, which found that a huge fraction of miRNAs exported by cells in culture are also 
associated with proteins and protein of the Argonaute (Ago) family [16, 17]. However, we 
believe that both mechanisms of miRNAs release are important and not necessarily mutually 
exclusive (for example EVs could embed miRNA-Ago complexes). 
Cell-to-cell communication is necessary for proper coordination, both during development 
and among different cell types within adult tissues. Before the research field of EVs exploded 
in the last years, cells were already known to communicate via secreted molecules, by cell 
surface molecules, or by direct cell-to-cell contact allowing for exchanges of cellular contents 
via different kind of channels and pores [18]. The concept that miRNAs are transported into 
extracellular spaces, together with the evidence that exchange of miRNAs between cells can 
be accomplished through extracellular transfer, led to a revolutionary hypothesis of the 
existence of an intercellular communication system by extracellular miRNAs. 
The present review focuses on the definition of extracellular miRNAs and examines evidence 
for their mechanism of transport outside and inside the cell. We will discuss recent studies 
that indicate extracellular miRNAs as novel mediators of intercellular communication, 
particularly as it relates to diabetes-induced cardiovascular complications.  
 
1. miRNA and complications of diabetes 
 
1.1 Diabetic Cardiomyopathy 
Diabetic cardiomyopathy is described as the diabetes-associated changes in the structure and 
function of the myocardium that is not directly linked to other confounding factors such as 
coronary artery disease (CAD) or hypertension[19]. We have previously reported 
upregulation of miR-1 and a consequential decrease in one of its target Pim-1 associated with 
the development of cardiomyopathy in STZ-induced type 1 diabetic mice [20]. Systemic 
administration of Pim-1 using an adeno-associated virus serotype-9, stopped the progression 
of cardiomyopathy through promotion of a pro-survival signalling [20]. Another study by 
Yildirim et al showed downregulation of miR-1 along with miR-499, -133a and -133b and 
upregulation of -21 in STZ-induced type 1 diabetic rats[21]. Intervention with an anti-oxidant 
(N-acetylcysteine) for 4 weeks helped to normalise the cardiac function along with restoration 
of the above mentioned miRNAs suggesting an inverse relationship of these miRNAs with 
oxidative stress in diabetic heart[21]. The contrasting reports from this two independent 
studies could be due to the difference in the species and also due to the different time points 
where the levels of miR-1 was measured[22]. As the diabetic cardiomyopathy progresses an 
increase in myocardial insulin resistance is observed, resulting in downregulation of glucose 
transporter 4 protein (GLUT 4). Lu et al reported upregulated expression of miR-223 to be 
associated with GLUT 4 expression in insulin-resistant heart[23]. In diabetic human and 
mouse heart, the expression of GLUT4 is downregulated. However GLUT4 expression was 
increased by miR-223 [23].  The authors speculate this as an adaptive response to restore 
normal glucose uptake in the pathophysiological condition[23]. Another complication 
associated with diabetic cardiomyopathy is mitochondrial dysfunction leading to increased 
oxidative stress and decrease in ATP production[24]. It was reported that miR-141 
upregulation modulated Slc25a3 gene which catalyses the transport of phosphate into 
mitochondrial matrix in cardiomyocytes of type 1 diabetic mice[24]. This could be a potential 
mechanism for low ATP production in diabetic heart. Collectively the studies show important 
implication of miRNAs in diabetic cardiomyopathy.  
 
1.2 Diabetic Nephropathy 
Diabetic nephropathy (DN) is one of the most important complications of diabetes 
mellitus, with 50% of diabetics requiring painful and costly dialysis [25]. DN is characterised 
by hypertrophy in the glomerular mesangium and tubular compartments along with podocyte 
dysfunction and ECM protein accumulation. Signalling pathways such as transforming growth 
factor-b (TGF-β) [26], Phosphoinositide 3-kinase-protein kinase B (PI3K-Akt) [27], Mitogen-
activated protein kinase (MAPK) family including P38, extracellular signal-regulated kinases 
(ERK), and c-Jun N-terminal kinases pathways have been reported to result in glomerular 
hypertrophy and ECM accumulation in DN [28-32]. Recent studies have demonstrated the 
role of miRNA in regulating the signalling pathways in the pathogenesis of DN. For example, 
increased expression of miR-192, miR-200b/c, miR-216a and miR-217 in mesangial cells (MCs) 
in type 1 (streptozotocin injected) and type 2 (db/db mice, leptin receptor mutant) diabetic 
mouse models [33-36]. miR-192 targets E-box repressors, ZEB1/2 in MCs to activate TGF-β 
leading to renal fibrosis proteinuria [37]. Interestingly this also result in upregulation of other 
miRNA in MCs such as miR-216a/miR-217 and miR-200b/c thereby increasing the collagen 
expression in DN [37]. miR-216a/217 is reported to activate Akt kinase by targeting Pten in 
MCs treated with TGF-β1 enhancing cellular hypertrophy [34]. miR-200b/c is also reported to 
activate Akt by targeting FOG2, an inhibitor of PI3K [36]. miR-21 was reported to target 
phosphatase and tensin homolog (PTEN) to induce the overactivation of Akt signalling 
pathway, followed by renal fibrosis and hypertrophy [38]. In db/db mice, miR-21 increased 
TGF-1 signalling by targeting Smad7; thus, an inhibitor of miR-21 was evaluated as a 
therapeutic target in this model [39]. These DN-inducing miRNA were found to be 
overexpressed in diabetic kidney and inhibiting these miRNA showed less severe phenotypes 
of DN in mice. For example, miR-21 knockdown by LNA-anti-miR-21 in diabetic kidneys of 
db/db mice significantly reduced microalbuminaria, renal fibrosis and inflammation [39]. In 
another study, LNA-anti-miR-192 attenuated DN in C57 type 1 diabetic mice by restoring the 
function of Zeb1/2 thereby downregulating ECM genes [40]. Also, miR-192-knock out mice 
were found to be protected from the key features of DN [41].  
Studies have shown that several DN-inducing factors such as TGF-β2, COL1, COL4, and NADPH 
oxidase subunit 4 (NOX4) are also targets of number of miRNA which are downregulated in 
DN. For example, all three members of the miR-29 family (miR-29a,b,c) were found to be 
downregulated in proximal tubular cells (NRK-52E), primary mouse mesangial cells, and 
human podocytes under high glucose/ TGF-β1 conditions[42, 43]. MiR-29 family directly 
targeted 3’UTR of the fibrotic genes, COL1 and COL4 resulting in their downregulation[43]. 
miR-29b is reported to have a renal protective role in db/db mice by inhibiting TGF-β/SMAD3 
signalling pathway and specificity protein 1/NF-κB-driven renal inflammation[44]. Fu et al 
reported significantly reduced levels of miR-25 in kidneys from diabetic rats and high glucose-
treated mesangial cells along with increase in NOX4 expression[45]. NOX4 levels could be 
restored by inhibiting miR-25. Lucifarase assays showed miR-25 directly binding to 3’UTR of 
NOX4 mRNA[45].  Collectively these studies show several miRNA are involved in regulating 
multiple biological effects in DN, with some taking part in the pathogenesis and development 
of the disease while others as DN preventers. These upregulated or downregulated miRNA 
may be potential targets for the treatment of DN.  
1.3 Diabetic Retinopathy 
Diabetic retinopathy (DR) is a major cause for loss of vision as well as visual disabilities in adult 
population in developed countries. The disease is characterized by impairment of blood 
vessels in retina, which, upon proliferation, leads to proliferative diabetic retinopathy (PDR); 
the abnormality of retinal blood vessels can also result in loss of function with leakage of fluid 
and lipids in retina as a consequence. In the case, when edema, caused by accumulation of 
fluid, affects central retina or macula, the end result could be blindness. Other consequences 
of DR include increased permeability of the retina, retinal ischemia and retinal 
neovascularization [46].  
During diabetes, hyperglycemia leads to cellular damage on vascular and neuronal levels via 
a number of mechanisms: elevated oxidative stress, activation of the protein kinase C (PKC) 
pathway, increased inflammation, production of advanced glycation end-products (AGE) and 
osmotic stress caused by accumulation of sorbitol through polyol pathway [47-50]. 
Furthermore, Abu El-Asrar et al. has reported that retinal endothelial cells undergo 
endothelial-to-mesenchymal transition, which promotes pathologic fibrosis in PDR [51]. 
The first evidence of miRNA involvement in pathogenesis of DR comes from Kovacs et al. 
study, where it has been demonstrated that there is a significant change in miRNA expression 
profile in retinas and retinal endothelial cells (RECs) between diabetic and control rats [52]. 
Specifically, expression of 80 miRNAs was upregulated while 6 miRNAs were downregulated 
in retinas of diabetic rats; moreover, 16 miRNAs were significantly increased whereas 104 
miRNAs were reduced in RECs of diabetic rats vs the control ones [52]. What is more, out of 
the 16 elevated miRNA in RECs 4 (miR-146, miR-155, miR-132, and miR-21) are induced by 
NF-κB, which is the main player in cellular inflammatory response and is also a significant 
pathological driver of early DR [52, 53]. Furthermore, it has been reported in another study 
that miR-200b expression is downregulated in the retinas of STZ-induced diabetic rats while 
its direct target gene, VEGF, was upregulated in the same condition, which leads to the 
leakage of blood vessels [54]. On the other hand, Murray et al. demonstrated that miR-200b 
levels are increased in retinas of genetically-induced diabetic (Akita) mice with the reduction 
of its target‘s, Oxr1, expression that exerts protection against oxidative stress [55, 56]. The 
opposing effects between the two studies might have arisen due to the fact there is a 
difference between STZ-induced and genetic model of diabetes. Interestingly, Feng et al. 
reported that hyperglycemia reduced the expression of miR-146a and, thereby, caused an 
overexpression of p300 transcription factor that resulted in accumulation of an extracellular 
matrix protein, fibronectin, in rats’ retinas, which occurs during retinopathy [57]. Further, it 
has been shown that oxygen-induced retinopathy (OIR) in mice brings the levels of miR-126 
down, thereby increasing the expression of VEGF, IGF-2 and HIF-1α via upregulation of p38 
and ERK signalling proteins; this leads to retinal neovascularization, which can result in 
blindness during diabetic retinopathy [58]. Finally, Mortuza et al. demonstrated that there is 
an elevation of miR-195 levels in retinas of STZ-induced diabetic rats that reduces the 
expression of SIRT1 and, consequently, upregulates fibronectin content; moreover, miR-195-
induced downregulation of SIRT1 promotes ageing-like changes in diabetic retinas of the rats 
[59]. 
1.4 Diabetic Neuropathy 
Diabetic peripheral neuropathy (DPN) is nerve damage occurring in the presence of diabetes, 
with prevalence greater than 50% in patients with long-standing disease.  The typical DPN is 
a chronic, symmetrical, length-dependent sensorimotor polyneuropathy [60]. Total 
hyperglycemic exposure is perhaps the most important risk factor and it is associated with 
metabolic derangements and cardiovascular risk factors [61]. Alterations of microvessels 
appear to be associated with the pathologic alterations of nerves [62].  Numerous studies try 
to elucidate the underlying mechanisms of this disease. Several reports have demonstrated 
that a variety of molecules are likely involved in the development of diabetic neuyropathy, 
such as protein kinase C, polyol, aldose reductase, advanced glycation end-products, reactive 
oxygen species, cytokines [63]. Only recently DPN has been associated with miRNA regulation.  
 miR-146a has been demonstrated to protect dorsal root ganglion neuros (DRG)  from 
hyperglycaemia-induced apoptosis thought regulation of TRAF6 and IRAK1 pathway. 
Interestingly, the administration of sildenafil, a phosphodiesterase type 5 inhibitor, in a 
mouse model of diabetic neuropathy increased miR-146a expression and the survival of DRG 
neurons [64]. On the other hand, Increased  expression of miR-146a and NF-κB, and a twofold 
decrease in the expression of TRAF6 were observed in the sciatic nerve of diabetic rats [65], 
showing that same miRNA could have opposite function in neurons from different tissues.  
Pro-survival activity of DRG in a rat model of diabetes has been also associated with 
upregulation of miR-29b and inhibition of SMAD3 [66]. 
Two studies using miRNA sequencing were able to identify miRNAs that were differentially 
regulated in neuropathy. DRG miRNA microarray identified significant changes in expression 
let-7i and miR-341 in diabetic mice [67] . Analysis of microRNA expression in the lumbar spinal 
dorsal horn of STZ-induced diabetic neuropathic pain (DNP) mice showed that miR-184-5p 
and miR-190a-5p are highly expressed in DPN tissues and they act as regulator of 
inflammation [68]. 
Polymorphisms have been identified in miR-128a, miR-27a and miR-146a and there were 
associated with susceptibility for diabetic polyneuropathy and for cardiovascular autonomic 
neuropathy [69]. 
 
1.5 Pancreatic -cells 
Pancreatic β-cells play a fundamental role in glucose homeostasis, releasing insulin in 
response to glucose levels in the bloodstream. Absence or malfunction of β-cells leads to 
type-1 diabetes (T1D), due to lack of insulin producing cells or type-2 diabetes (T2D), 
characterized by the inability to increase insulin levels to sufficiently stimulate glucose uptake 
[70].  Expression profiling experiments identified a large set of miRNAs has been implicated 
in β-cell development, including miRNA belong to the miR-16 family  (miR-15a/b, miR-16, miR-
195)[71], miR-503, miR-541, miR-214 [72], miR-9, miR-7, miR-376 and miR-375 [73], among 
them. 
miR- -cells miRNA in T2D patients and in the pancreatic 
islets of obese diabetic mouse models (ob/ob)[74]. Expression of miR-375 in adult β-cell islets 
is downregulated when high levels of glucose are available [75]. Low levels of miR-375 induce 
insulin secretion by de-repression of its targets Mtpn [76] and PDK1 [77] while overexpression 
of miR-375 exerts opposite effects on insulin secretion [77]. 
Stoffel group, using genetic approaches, showed that conditional deletion of miR-7a resulted 
in improved glucose tolerance by increasing β-cell secretion of insulin [78]. Interestingly, 
modulation of miR-7a expression in β-cells did not affect proliferation and apoptosis, showing 
that miR-7 is dispensable for the maintenance of endocrine β-cell mass. The same Authors 
has demonstrated that miR-200 family is strongly induced in islets of diabetic mice [78]. 
-cell–specific overexpression of miR-200 in mice is sufficient to induce beta 
cell apoptosis. Conversely, mir-200 -cell apoptosis and ameliorates 
T2D.  Regulation of an anti-apoptotic and stress-resistance network that includes the protein 
Dnajc3 and the caspase inhibitor Xiap is at the base of miR-200 family mechanism [78]. 
 
 
 
2. Transporters for extracellular miRNAs  
Extracellular miRNAs can be found in high concentrations in body fluids, where they maintain 
good stability despite the high RNase activity indicating that some mechanisms are in place 
to confer the miRNAs protection from digestion [79-81]. Indeed, naked miRNAs added to 
plasma are degraded in <5 sec, whereas circulating miRNAs are stable for many hours under 
the same conditions [82]. This phenomenon reflects the presence of an endogenous 
mechanism for the remarkable stability of miRNAs. The miRNA resilience may be explained 
by them being packaged in membrane encapsulated vesicles including exosomes[83], 
microvesicles and apoptotic bodies[84] and/or be protected by RNA-binding proteins [85] 
that offer protection against RNase activity.  
2.1 miRNAs transport via exosomes  
Exosomes are a subtype of membrane vesicles of approximately 30-100nm in size that are 
released from the endocytic compartment of live cells [86]. Endosomes originate from inward 
budding of the cytoplasm membrane. Surface proteins of plasma membrane may be 
transferred to the inner membrane of the endosomes during this process. Invagination of 
endosomes generates intraluminal vesicles (ILVs) or exosomes with cytoplasmic components 
or transmembrane proteins within them. Endosomal sorting complex required for transport 
(ESCRT), mediates budding of ILVs[87].  Accumulation of exosomes in the lumen of 
endosomes results in multivesicular bodies (MVBs).  MVBs can either fuse with lysosomes to 
follow a degradation pathway or fuse with plasma membrane releasing exosomes to the 
extracellular space [88]. Accumulation of specific molecules such as ceramide and Ca2+ 
dependent scramblase favours pinching off the membrane and eventual release of the 
contents into the extracellular space (reviewed in [89]). Although initially considered as cell 
debris, exosomes have now emerged as important regulators of biological functions via 
transfer of genetic materials. Once released, exosomes can either target neighbouring cells 
or enter the blood stream, thus potentially reaching distant cellular targets. In 2002, 
exosomes were first reported to transfer information between cells but it was not until 2007 
that a seminal study by Valadi et al proved exosomes to contain functional miRNAs which can 
be delivered to another cell [83].  MiRNA-214 (miR-214) plays a dominant role in exosome-
mediated signalling between ECs. EC–derived exosomes stimulated migration and 
angiogenesis in recipient cells, whereas exosomes from miR-214–depleted ECs failed to 
stimulate these processes [90].   
In a recent study, authors performed a deep sequencing analysis on small RNAs isolated from 
ECs and their corresponding exosomes [91]. The authors demonstrated that different RNA 
classes show different distributions between ECs and exosomes. An in-depth analysis of 
miRNA sequences shows that 5p, 3p and stem-loop fragments of identified miRNAs are 
differentially distributed between cells and exosomes. In addition, exosomes are enriched 
with miRNA-like fragments derived from snoRNAs, vault RNA, yRNAs and the degradation 
products of long coding RNAs [91]. These findings suggest that, besides possible targeted 
transport of small RNAs to exosomes, there is a mechanism for localized degradation of RNA 
in the proximity of multivesicular bodies and the subsequent disposal of RNA fragments 
through exosomes [91]. 
 
2.2 miRNAs transport via apoptotic bodies 
Cell apoptosis is an important mechanism by which unnecessary cells are removed in 
multicellular organisms. Cells undergoing apoptosis release small sealed membraneous 
vesicles termed as apoptotic bodies. Apoptotic bodies consist of cytoplasm with tightly 
packed organelles with or without nuclear fragment and are subsequently phagocytozed by 
macrophages and degraded within phagolysosomes. [84, 92, 93].  
Zernecke et al found that EC at atherosclerotic sites secreted apoptotic bodies into the 
circulation which where engulfed by phagocytes triggering secretion of cytokines or growth 
factors[84]. The apoptotic bodies secreted by the ECs showed unique signature of 
miRNAs[84]. One of the highest expressed miRNAs was miR-216, implicated as a key regulator 
of VEGF and FGF signalling in ECs[84]. The study showed that dying ECs communicate with 
neighbouring cells via apoptotic bodies packaged with specific miRNAs resulting in a healing 
vascular protective responses [84].  
2.3 miRNAs transport via microvesicles 
Microvesicles are all cell-derived vesicles that are enclosed by a lipid bilayer, ranging from 
50nm to 1,000 nm in diameter depending on their origin. In contrast to exosomes that are 
derived from the endolysosomal pathway, microvesicles are generated by budding from the 
plasma membrane. Therefore, although they are heavily enriched in phosphatidylserine, the 
membrane composition of microvesicles reflects that of the parent cell more closely than 
does the membrane composition of exosomes. Microvesicles are characterized by specific 
cytoplasmic proteins, certain lipid raft-interacting proteins and RNAs [94]. 
Zhang et al. demonstrated that miR-150 from monocytic cells was delivered into ECs via 
microvesicles, and reduced the expression of c-Myb, resulting in the increase of cell migration 
in EC both in vitro and in vivo [95].  
In addition, another study also showed that the microvesicles from CD34+ peripheral blood 
mononuclear cells exhibited proangiogenic activity in ECs via the transfer of miR-126 [96].  In 
similar context, Cantaluppi et al. reported that EVs released from endothelial progenitor cells 
(EPC) contains miR-126 and miR-196 and enhanced islet EC proliferation, migration, anti-
apoptosis, and angiogenesis [97].  
A recent study demonstrated that platelets can remotely modulate vascular EC apoptosis 
through releasing miRNA-223-containing microvesicles. Exogenous platelet miR-223 can 
decrease the level of insulin-like growth factor 1 receptor and thus promotes HUVEC 
apoptosis induced by advanced glycation end products. Moreover, Ismail et al. found that EVs 
from macrophage contained miR-223, and transport miR-223 in a functionally active status to 
target cells, including ECs [98]. 
 
2.4 miRNAs  transport via proteins and lipoproteins 
Nucleophosmin 1 (NPM1) and Argonaute 2 (Ago2) are two proteins that are confirmed as 
miRNA carriers. NPM1 is a ubiquitously expressed nucleolar protein involved in exporting 
RNAs and ribosomal proteins to cytoplasm[99]. The Ago2-miRNA complexes forms a main 
part of RISC complex during gene regulation and they are present in human plasma[100]. 
However it still needs to be confirmed if this is the intracellular Ago2-miRNA complex or 
whether this originates from disassembled Ago2 loaded with a new mature miRNA when 
already in the extracellular compartment. Extracellular miRNAs are also transported by high-
density lipoproteins (HDL) and low-density lipoproteins (LDL). It was initially showed that 
lipoprotein-bounded miRNAs were not very different in CAD patients and they could not be 
easily transferred to vascular cells and circulating monocytes[101]. However, later studies by 
Vickers et al rather suggested that the HDL-miRNA profile of normal subjects is significantly 
different from that of people with familial hypercholesterolemia [85]. This is in line with the 
concept that HDL can attracts different molecular partners in health and disease, thus eliciting 
variable effects on vascular function dependently on those[102] [103]. In particular, HDL from 
type 2 diabetes mellitus or metabolic syndrome patients cannot reproduce the endothelial-
protective effects similar to the HDL from healthy subjects[104]. Additionally, reconstituted 
HDL attracted different miRNAs when injected into the systemic circulation of atherosclerotic 
mice in comparison to healthy mice.  The latter suggest that HDL can bind with miRNAs after 
the  miRNAs have been released in the circulation by the producing cells [85]. The functional 
importance of HDL-conjugated miRNAs is suggested by studies where HDL-miRNAs from 
atherosclerotic or control subjects were used to stimulate hepatocytes cells, which responded 
with differential gene expression changes [85].  The same study also showed that the cellular 
export of miRNAs to HDL is regulated by neutral sphingomyelinase and that the HDL delivery 
of miRNAs to recipient cells is mediated via a scavenger receptor class B type I [85].  HDL 
delivery of both exogenous and endogenous miRNAs resulted in the direct targeting of mRNA 
reporters. [85].  Taken together, the observations of Vickers et al indicate that HDL transport 
and deliver miRNAs, with functional consequences on the recipient cells and that the miRNAs 
transported by HDL could be responsible for the heterogeneity in vascular response to HDL. 
It would be of extreme importance to expand the HDL-miRNAs studies to the diabetes setting 
with a precise cardiovascular focus.  
 
3. Mechanisms of miRNAs export and transfer  
3.1 Selective miRNAs export in extracellular vesicles 
It is emerging that the quality and concentration of miRNAs contained in EVs is dictated by 
the type of producing cells as well as by forced changes in their molecular profile and exposure 
to different environmental conditions. For example, EVs secreted by KLF2-transduced or 
shear-stress-stimulated endothelial cells are enriched in miR-143/145 [105]. The vesicular 
export mechanism for miR-143 induced by the shear stress responsive transcription factor 
KLF2 in endothelial cells has been recently suggested to depend on Rab7a/Rab27b, two 
GTPases involved in the coordinators of membrane trafficking[106]. For what concerns the 
setting of diabetes cardiovascular and renal complications, we showed that miR-503 is 
contained in microparticle secreted by ECs, but not by pericytes and that diabetes-mimicking 
culture conditions increase the abundance of miR-503 in the EC-released microparticles [8]. 
Moreover, cardiac myocytes from type 2 diabetic rats release exosomes with higher miR-320 
in comparisons to cells from non-diabetic controls [107]. These studies showed that both the 
aforementioned alterations provoke detrimental functional consequences on the recipient 
vascular cells, namely pericytes and EC, respectively [8] [107]. Exosomes from kidney cells are 
also affected by exposure to high D-glucose (HG) concentration. For example, miR-145 
increased in both cultured mesangial cells and their exosomes in response to exposure to HG 
[108].  
The mechanisms whereby miRNAs are sorted to EVs are not known, if not very preliminary.  
Some evidence of a non-random sorting of miRNAs in exosomes comes from Guduric-Fuchs 
et al., who found that a specific set of miRNAs, such as miR-142-3p, miR-150 and miR-451, are 
preferentially sorted in exosomes from HeLA cells [109]. Moreover, Squadrito et al performed 
RNA profiling of macrophages and their exosomes and presented evidences 
that miRNAs sorting to exosomes is modulated by changes of the miRNA target mRNAs in the 
cells. They went on to show that perturbing the expression of individual miRNAs or their 
targeted mRNAs promotes bidirectional miRNA relocation from the cell cytoplasm/P bodies 
to MVBs, thus controlling miRNAs sorting to exosomes [110]. Equivalent studies in cultured 
cardiovascular cell types exposed or not to diabetes or diabetes mimicking conditions are still 
lacking. In vivo studies showed that the exosomal miRNAs in type 1 diabetic patients is 
affected if the patients have incipient diabetic nephropathy. In details, miR-130a and miR-145 
were enriched, while miR-155 and miR-424 were reduced in urinary exosomes from diabetic 
patients with microalbuminuria [108]. The miR-145 data were confirmed using an animal 
model of diabetic nephropathy, where miR-145 was also found increased in the glomeruli 
[108]. Interestingly, the pool of exosomal miRNAs circulating in diabetic subjects might be 
regulated by life style improvements, such as regular exercise [111]. In fact, Chaturvedi et al 
found that exosomal miR-455 and miR-29b increase during exercise in db/db, a mouse model 
of type 2 diabetes. Both miRNAs target metalloprotease-9 (MMP9), which has damaging 
effects on extracellular matrix remodelling. In line, tissutal MMP9 was found reduced in active 
mice [111]. Together these above reported studies suggest the existence of regulatory 
mechanism(s) determining the miRNA exosomal sorting, which can be altered by different 
physio-pathological conditions. 
 
 3.2 Mechanism of miRNAs loading into exosomes 
To this date only a few main mechanisms of miRNA loading into exosomes are described in a 
certain degree of detail. The first system is based on neural sphingomyelinase 2 (nSMase2)-
dependent pathway. The nSMase2 enzyme that regulates ceramide biosynthesis. The earliest 
evidence comes from Kosaka et al, who found that nSMase2 inhibition resulted into 
decreased secretion of miRNAs via exosome, while miRNA secretion was enhanced by 
elevating the activity of nSMase2 [112]. It has been then was confirmed that overexpression 
of nSMase2 increased levels of miRNAs in exosome and the downregulation of the enzyme 
reduced the number of exosomal miRNAs [113]. Another mechanism of miRNA sorting into 
exosomes is dependent on miRNA motif and sumoylated heterogeneous nuclear 
ribonucleoproteins (hnRNPs). In detail, it was found that specific short miRNA sequences, 
called the EXOmotifs, determine the miRNA localisation into exosomes [114]. Moreover, it 
was identified that a particular member of hnRNPs, hnRNPA2B1, which has been previously 
demonstrated to coordinate mRNA trafficking to axons in neural cells [115], binds to the 
EXOmotifs on miRNA, thus driving the miRNA loading into exosomes [116]. The hnRNPA2B1-
dependent miRNA sorting in exosomes is mediated by sumoylation of the protein [116]. 
In another study Koppers-Lalic et al. demonstrated that there is 30% difference in the amount 
of miRNAs in the total small RNA content between the cellular (50%) and exosomal (20%) 
fraction of B cells with a discordant miRNA distribution between exosomes and the intra-
cellular compartment [117]. Specifically, it was found that miRNAs that are adenylated in their 
3’ end are over-represented in the cellular fraction, whereas 3’ end uridylated miRNAs are 
enriched in the exosomes [117]. This study suggests that miRNAs with a sequence that 
contains uridines at 3’ end are preferentially loaded in exosomes, which is another evidence 
of the exosomal orting signal [117]. The aforementioned mechanisms are represented in 
Figure 1. 
Another mechanism of exosomal miRNA loading involves the miRNA-induced silencing 
complex (miRISC) pathway. In particular, it has been reported that exosomes contain Ago2, 
which is a part of miRISC and mediates interaction between mRNA and miRNA [118]. 
Moreover, in HEK293T cells, the Ago2 knockdown led to reduction in the exosomal export of 
a miRNA pool, such as miR-451, miR-150, and miR-142-3p [109]. Further, it has been 
demonstrated that Ago2 and another miRISC component of miRISC (GW182) associate with 
MVBs [119]. Lee at al. reported that inhibition of MVB formation results in decreased 
numbers of miRISC associated with P-bodies, which are physically attached to MVBs [120]. In 
addition, Squadrito et al. demonstrated that activation of bone marrow-derived macrophages 
via treatment with IL-4 led to differential distribution of miRNAs in exosomes [110]. In detail, 
the study shows that the reduction in cellular levels of the target mRNAs of specific miRNAs 
in response to cellular activation leads to increase in the number of those miRNAs in 
exosomes, thus suggesting that miRNA sorting in exosomes is a feedback mechanism, which 
balances the cellular levels of miRNA and its targets [110].  
Cha et al proposed another mechanism of miRNA loading into exosomes based on KRAS 
protein, a GTPase which is encoded by an oncogene that is often mutated in colorectal cancer 
cells [121]. It has been found that the presence of mutant KRAS allele in the cell affects sorting 
of a particular set of miRNAs in exosomes. The study demonstrates that miR-100, which 
negatively regulates metastatic cancers, is downregulated in mutant KRAS cells, but elevated 
in the exosomes derived from the same KRAS cells, implying that cellular miR-100 decrease is 
a result of its sorting and secretion in exosomes [121]. It was reported that the inhibition of 
the nSMase resulted in three-fold increase in intracellular miR-100 levels, suggesting that the 
enzyme plays an important part in KRAS-dependent miRNA exosomal sorting [121]. 
In the in vivo cardiovascular setting, it was shown that CAD is associated with decreased 
miRNAs loading into MPs [122]. Data in the context of diabetes are still lacking and more 
research is needed.   
 
3.3 Cell-to cell communication of extracellular miRNA 
MiRNAs, which are secreted via EVs, are thought to exhibit cell-to-cell communication via 
paracrine and endocrine routes. There are two main known functions of the secreted miRNA 
in EVs: the first one is a conventional downregulation of the target genes in the recipient cells; 
the second function involves activation of the immune response by EV interacting with 
immune cells. There are several examples of the first mechanism. Zernecke et al found that 
apoptotic ECs in atherosclerotic plaques secrete miR-126 within the apoptotic bodies to 
target surviving recipient ECs, thus exerting protection from further atherosclerotic damage 
via downregulation of the miR-126 target RGS16 expression and recruitment of Sca-1+ 
progenitor cells [123]. Another study has illustrated that miR-143 and miR-145 secreted by 
EVs from ECs under shear stress are taken up by the smooth muscle cells (SMCs), where they 
bring about the downregulation of their target genes, inducing atheroprotective effects [105]. 
Recently, the Baker group has identified the presence of miR-143-3p in pulmonary artery 
SMCs (PASMCs)-derived exosomes. Using assays with pulmonary arterial ECs (PAECs), they 
also demonstrated a paracrine pro-migratory and pro-angiogenic effect of the miR-143-3p 
enriched exosomes from PASMCs [124].  Moreover, Finn et al demonstrated that serum MPs 
from CAD patients show a deficiency in a glycoprotein (developmental endothelial locus-1: 
Del-1), which mediates the uptake of MPs by ECs. This caused a reduced uptake of MP-
embedded miRNAs (miR-17, miR-19a, miR-21, miR-92a, miR-146a, miR-222, and miR-223) in 
recipient cultured ECs [122]. We have recently shown that in mice with diabetes and limb 
ischemia, the secretion of miR-503 in endothelial MPs is increased via a p75NTR-dependent 
mechanism. P75NTR is an atypical neurotrophin receptor, which we already showed to be 
induced by diabetes in ECs with detrimental functional consequences in vitro and in vivo [8, 
125, 126]. In cultured ECs, p75NTR activates the NF-kB signalling, which in turn induce miR-503 
transcription and the MP shedding by triggering the expression of Rho kinase [8]. Intriguingly, 
MPs containing miR-503 are taken up by co-cultured pericytes, which respond with the 
downregulation of the miR-503 target genes, EFNB2 and VEGFA, and finally an impairment in 
their migration and proliferation capacities [8]. This study suggests how the crosstalk between 
different types of vascular cells under diabetes is modulated by miRNAs secreted in EVs. As 
an example of the immune system-mediated EV actions come from Fabbri et al, who reported 
that exosomal miR-21 and miR-29a from lung cancer interact with and activate toll like 
receptors (TLRs) on surrounding macrophages, which leads the immune cells to secrete 
prometastatic cytokines resulting in the growth and spread of the tumour. This is a novel 
example of tumour-immune cells communication [127].  
More recent literature suggests an involvement of cancer-derived exosomes in determining 
the site of metastatic growth [128]. Hoshino et al demonstrated that exosomes from tumor 
cells with a differential tropisms (lung, liver, or brain) fuse preferentially with resident cells at 
their predicted destinations to prepare the pre-metastatic niche. Exosome proteomics 
revealed distinct integrin expression patterns, in which the exosomal integrins α6β4 and α6β1 
were associated with lung metastasis, while exosomal integrin αvβ5 was linked to liver 
metastasis [128]. Integrins targeting in the exosome producing cells could decrease 
metastatic growth. In additional, clinical data indicate that exosomal integrins could be used 
to predict organ-specific metastasis in patients. The role of exosomal miRNAs has not been 
investigated in this study, but miRNAs could contribute to the metastatic trigger once 
delivered via exosomes. These new concepts could be relevant also in the context of diabetes 
and cardiovascular disease, for example for predicting the organs that will be targeted by 
complications in patients with diabetes mellitus. Of course, more research is needed to evolve 
from these hypotheses. 
 
4. Role of extracellular miRNA in diabetes-induced cardiovascular disease 
MiRNAs transport via EVs has been implicated with the development of diabetic 
cardiovascular complications. For example, while cardiomyocytes from healthy rats were 
shown to promote angiogenesis responses in vitro; the same cell type cultured from type 2 
diabetic rats inhibited the proliferation and migration of co-cultured ECs in vitro. These 
detrimental effects were eliminated when treated with exosome inhibitor GW4869 [129]. 
Further investigations showed an increased expression of miR-320 in exosomes extracted 
from diabetic rat cardiomyocytes[129]. Importantly, the exosomal miR-320 can be 
transferred to the EC leading to inhibition of angiogenesis favouring responses[129].  
Recent evidences suggest that reduced miR-126 expression levels are partially responsible for 
impaired vascular repair capacities in diabetes (Zampetaki, Kiechl et al. 2010). Patients with 
type 2 diabetes showed a significant reduction in the level of vesicular miR-126, with non-
vesicle-associated miR-126 was unchanged. Decreased vesicle enrichment of miR-126 was 
observed prior to the manifestation of diabetes and was correlated with severity of the 
disease. In vitro experiments in this study showed that exposure to HG reduced the miR-126 
concentration in EC-derived apoptotic bodies.  These data are in line with the publication from 
an independent laboratory. Jansen et al. also demonstrated that endothelial microparticles 
prepared from healthy subjects promote re-endothelialisation after endothelial injury in mice 
and EC migration and proliferation in vitro by transferring functional miR-126 to target ECs 
[130]. They also reported decreased miR-126 inside endothelial microparticles prepared from 
patients with stable CAD and diabetes. A recent study reported that first-trimester primary 
trophoblast cells when incubated with D-glucose (25mM) in hypoxic conditions significantly 
increased the release of exosomes[131]. These exosomes significantly increased the release 
of cytokines such as granulocyte macrophage colony stimulating factor, IL-4, IL-6, IL-8, 
interferon-v and TNF-alpha from human umbilical vein endothelial cells (HUVECs) compared 
to controls[131].  
We have previously identified that miR-503 expression is increased in ischemic limb muscles 
of type 1 diabetic mice and in ECs enriched from these muscles. Moreover, adenoviral 
administration of decoymiR-503 to the ischemic adductor of diabetic mice corrected 
diabetes–induced impairment of post-ischemic angiogenesis and blood flow recovery [7]. ECs 
and pericytes establish a cellular crosstalk in the microvasculature, which is fundamental for 
the regulation of angiogenesis, microvascular stabilization and permeability, but this 
protective mechanism is disrupted under diabetes. Our study established that under diabetic 
conditions, endothelial MPs carrying miR-503 interfere with ephrin-B2 and VEGFA expression 
in pericytes, further blocking post-ischaemic angiogenesis and vascular integrity [8]. 
Additionally, we have recently provided the first evidence that several miRs are differentially 
expressed in circulating pro-angiogenic cells (PACs) enriched from critical limb ischemia (CLI) 
patients with or without diabetes [132]. CLI-PACs showed higher levels of miR-15a and miR-
16 and of the primary transcript pri-miR-15a/16a1. Overexpression of miR-15a and miR-16 
impaired migration and survival in healthy PACs whereas inhibition improved the situation 
[132]. In addition we also provided preliminary evidence that in type 2 diabetic patients 
undergoing revascularization for CLI, increased circulating levels of miR-15a and -16 are 
associated with higher risk of limb amputation at one year follow-up, thus opening some 
scope for the use of extracellular miRNAs as predictive biomarkers in diabetic patients 
afflicted by severe cardiovascular complications [132]. 
Another group has reported that regenerative properties of circulating PACs were due to the 
transfer of exosomes enriched in miR-126 [133]. However exosomes from PACs isolated from 
blood samples of diabetic patients showed reduced miR-126 levels and impaired vascular 
repair potential [133].  
We believe these aforementioned studies are of paramount importance to stimulate more 
fundamental research utilitarian to understand and then therapeutically manipulate the 
mechanisms leading to miscommunication between cells in the diabetes setting. Additionally, 
the possibility to develop extracellular miRNAs as predictive biomarkers of cardiovascular 
events in diabetic patients could help the monitoring and management of these patients, 
which is currently far from optimal. Biomarkers studies will require work on large populations 
of diabetic patients that are well characterized at baseline and at different follow-up times. 
 
5. The future of miRNAs transport  
The findings described in this review detail the analysis of extracellular miRNAs along with 
providing a better understanding of miRNAs sorting to distinct secretory pathways and 
carriers. The regulation of miRNAs secretion and mechanisms of targeting is believed to 
generate opportunities to identify novel strategies for screening, monitoring and curing 
cardiovascular complications in diabetic patients. 
Major achievements will be to determine which specific RNA sequences (if any) are necessary 
to export miRNA into the circulation and how diabetes could impact on these mechanisms.  
Comparative analysis of the sequences of miRNAs enriched in either cells or different types 
of EVs may provide information about possible mechanisms for selective incorporation of 
miRNAs into exosomes and other EVs and how these are affected under pathologies. 
Interestingly, miRNAs carrying an extensive 3’ uracil residues added to their mature sequence 
have been proposed as important for selective incorporation into exosomes, whereas 
additional adenosines were detected at the 3’ end of cellular retained miRNAs [117].  
However, we cannot know if these potential regulatory mechanisms are maintained across 
cell type and under diseases and how these could explain changes induced by the 
environment or the cell type identity in the EV miRNAs cargo. 
The export of miRNAs is likely to be regulated by cellular signalling. However, only few studies, 
described in the above section 2, have tried to start and investigate the regulatory 
mechanisms that govern the packaging of miRNAs into various carriers and miRNA secretion 
from cells. Therefore, the clarification of molecular mechanisms that regulate the secretion 
of miRNAs is a critical step for understanding their subsequent transport in the circulation. 
On the other side, we must admit that the investigatory tool-kits currently available for 
extracellular miRNAs and EV research are not optimized to address these ambitious questions 
and the development of new experimental approaches should parallel the investigation of 
our research questions in the regulatory mechanisms of extracellular microRNAs sorting and 
uptaking by recipient cells. 
Of vital importance will be to discover the mechanisms that regulate extracellular miRNA 
stability. For example, protein typing of miRNA carriers, such as microvesicles and exosomes, 
should facilitate not only the recognition of circulating EVs and their cellular origin 
understanding, but also the identification of protein factors contributing to the stability of 
miRNA in the circulation. 
One of the key questions that need to be addressed is how extracellular miRNAs, whether 
encapsulated in EVs or in complexes with proteins, gain access to target tissues or cells. It is 
important to determine which receptor-mediated mechanisms exist between miRNA carriers 
and target cells to regulate the transfer of vesicular miRNAs. Recent evidences strongly 
suggest that integrins are involved in exosomes homing to different types of cells and organs 
[8, 128] Thus far the proposed mechanisms for how miRNAs are delivered to recipient cells 
depend on whether they are part of EVs (and what type of EV), lipoproteins, or Ago2 
complexes. Receptor-mediated uptake would be expected for protein-associated miRNAs 
[134] and exosomes [135]. It is possible that part of the circulating Ago2-miRNA complexes 
are contained in EVs and use the vesicles as a shuttle system [119]. However, it is not clear 
how the recipient cells would take up Ago2-miRNA complexes, when these are not embedded 
in EVs or attached to lipoproteins. Importantly, receptors to transfer double-stranded RNA 
have been identified in mammals [136].  
Because secreted miRNAs can be detected in biological fluids and can reflect the physiological 
status of the cells and organs they originate from, miRNAs could potentially serve as clinical 
biomarkers [137]. In order to reinforce the role of circulating miRNAs as biomarker of 
cardiovascular disease insurgence and evolution in diabetic patients, future studies will need 
to focus on deciphering the cellular origin of the extracellular miRNAs.  
The challenges of miRNA targeting in vivo require the development of effective inhibitors that 
will decrease off-target effects. Naked miRNAs or anti-miRNAs are highly charged and often 
unstable in the circulation, thus packaging them into EVs can increase their potential for 
effective delivery and exciting therapeutic uses. EVs are better tolerated by the immune 
system than chemical nanoparticles as they represent natural transporters derived from 
endogenous cells. Moreover, this alternative approach could significantly reduce the dose of 
“miRNA drugs” and miRNA inhibitors necessary for treatment. Therefore, the investigation of 
the ability of such EVs carrying miRNAs to repair damaged tissues or vessels would be crucial 
for a future use in cardiovascular regeneration. For these studies, imaging techniques, 
innovative tracking systems and genetic animal models are required in order to assess the 
effectiveness of delivery of EVs in the target tissues. 
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